Plasma Level of miR-5193 as a Novel Biomarker for Diagnosis of HBV-Related Hepatocellular Carcinoma

Niloofer Moradi 1, Mahdi Paryan 2,*, Behzad Khansarinejad 1, Hossein Sarmadian 4 and Mahdieh Mondanizadeh1, 5,**

1Department of Biotechnology and Molecular Medicine, Arak University of Medical Sciences, Arak, Iran
2Department of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran
3Department of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran
4Infectious Diseases Research Center, Arak University of Medical Sciences, Arak, Iran
5Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran

*Corresponding author: Department of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran. Email: mparyan@gmail.com
**Corresponding author: Arak University of Medical Sciences, Arak, Iran. Email: m_mondanizadeh@yahoo.com

Received 2018 September 21; Revised 2019 January 19; Accepted 2019 February 14.

Abstract

Background: Chronic infection with hepatitis B virus (HBV) is related to more than 50% of all cases of hepatocellular carcinoma (HCC). The HBx protein of the virus plays an important role in carcinogenesis through different mechanisms, including interaction with the Notch1 signaling pathway. Several microRNAs have also been shown to play essential roles in the carcinogenesis of HCC, and the molecules can be considered the novel biomarkers for the diagnosis of different types of cancer.

Methods: In the present study, the expression levels of four bioinformatically predicted microRNAs, including miR-214, miR-6510, miR-5193, and miR-34a, were compared in individuals with HBV-associated HCC and controls in order to assess the diagnostic utility of these microRNAs as noninvasive biomarkers. Seventy three plasma samples were subjected to RNA extraction, and the microRNA expression profiles were assessed by RT-qPCR. The expression of miR-103 was used as the endogenous reference for the normalization of quantitative data.

Results: The plasma expression of all miRNAs was significantly lower in the HCC group, but the downregulation was most marked for the newly described molecule, miR-5193 (-18.86 folds and -5.71 folds compared to healthy individuals and chronic HBV patients). Another novel microRNA, miR-6510, was downregulated by -4.23 folds (P = 0.001). The results of the ROC curve analysis indicated that the differential expression of miR-5193 could distinguish HCC patients with high sensitivity and specificity.

Conclusions: The study microRNAs may have a role in HCC development and progression. In addition, miR-5193 can be potentially used as a non-invasive biomarker for the detection of HBV-induced HCC.

Keywords: Biomarker, HBV, HCC, Hepatocellular Carcinoma, MicroRNA

1. Background

Approximately, 257 million people are suffering from chronic infections with hepatitis B virus (HBV) worldwide, and about 887000 of these infected individuals die annually from end-stage hepatic diseases (1, 2). Chronic HBV infection also increases the risk of hepatocellular carcinoma (HCC), which is the fifth most prevalent malignancy and the third cause of cancer-related mortality (3, 4). The incidence of the disease is more than 700,000 cases annually (5), and approximately 50% of the HCC patients suffer from HBV infection (6). Carcinogens, such as aflatoxin or some other chemicals, are believed to act as cofactors for the development of this cancer (7). The HBV x protein (HBx) has a key role in the carcinogenesis associated with the virus, and transgenic mouse models harboring the HBx gene may develop liver cancer (8). HBx induces its effects by transcriptional activation, modulation of apoptosis, deregulation of cell cycle progression, and inhibition of repair of damaged cellular DNA (9). This protein is capable of activating the Notch1 signaling pathway, which may further lead to the development and progression of HCC. Therefore, treatments that decrease Notch1 expression may have anti-tumor effects (10-15).

One characteristic feature of HCC is that effective therapeutic strategies, including surgery and liver transplantation, are only effective in the first stages of tumor formation (16). HCC is a clinically and pathologically heterogeneous disease, so monitoring of patients for early detection of the malignancy is of great importance (16). Al-
though many diagnostic methods including transabdominal ultrasound and surveillance by contrast-enhanced computed tomography are available for the diagnosis of HCC, these methods are not cost-effective and their validity is dependent on the quality of the machines and the experience of the examiner. On the other hand, con-lidity is dependent on the quality of the machines and HCC, these methods are not cost-effective and their va-

3. Methods

3.1. miRNA Prediction Using Bioinformatics Tools

The nucleotide sequences of Notch1 and HBx genes were acquired from NCBI (http://www.ncbi.nlm.nih.gov/gene). The miRNAs that target Notch1 were predicted using different bioinformatics algorithms and tools, including Targetscan, DIANA, miRWalk, miRBase, PicTar, Miranda, microcosm target, and miRNApath. The HBx-targeting miRNAs were predicted using databases such as miRBase and Vir-Mir. After selecting miRNAs that targeted Notch1 and HBx with the highest probability, three miRNAs of the nine predictors for HBx and one miRNA of the five predictors for Notch1 were chosen for further experimental analyses.

3.2. Primer Design

The sequences of the predicted miRNAs were obtained from miRBase. The expression of miR-103 served as the reference target for the normalization of miRNAs expressions. Reverse transcription-specific stem-loop primers and miRNA specific primers (24) were designed using the AlleleID7 and GeneRunner software. The Mfold database was also used to assess the secondary structures. NCBI BLASTn tool was used to evaluate the specificity of the designed primers. The sequences of the primers are presented in Table 1.

3.3. Patients and Samples

A total number of 73 plasma samples, including 23 samples from individuals with HBV-related HCC, 25 from healthy individuals, and 25 from patients with chronic HBV who had no sign of HCC, were used in this survey. The HCC specimens were collected from the Liver and Digestion Research Center (Taleghani Hospital, Tehran, Iran). These samples had been taken from 10 females and 13 males, with a mean age of 57 years (SD: 8.9; range: 44 to 72 years), not receiving cancer-related treatment including chemotherapy, radiotherapy, or surgery. The chronic HBV samples were collected from the Imam Reza Clinic (Arak University of Medical Sciences, Arak, Iran) and had been obtained from patients suffering from chronic HBV for more than 15 years with no sign of HCC. These samples had been collected from 12 females and 13 males, with a mean age of 48 years (SD: 10.2; range: 39 to 75 years). The samples from healthy individuals, including 12 females and 13 males, with a mean age of 49 years (SD: 10.1; range: 40 to 74 years), were obtained from the Arak Reference Laboratory (Arak University of Medical Sciences, Arak, Iran). All samples were stored at -70°C prior to analysis. The study was approved by the Ethics Committee of Arak University of Medical Sciences (ethics number: 1394.207).

3.4. miRNA Extraction and Reverse Transcription

MicroRNAs were purified from plasma using RNX-Plus kit (SinaClon, Iran) with some modifications to the manufacturer’s protocol. For cDNA synthesis, about 1 µg of RNA was mixed with 1 µM of specific stem-loop RT primers and incubated at 75°C for 5 minutes. A mix containing 100 units of M-MuLV RT-enzyme (Vivantis, Malaysia), 1x RT-buffer, and 400 µM of dNTP were added to the tube. Finally, the RT reaction mixtures were incubated at 25°C for 15 minutes, 37°C for 15 minutes, 42°C for 45 minutes, and 75°C for 10 minutes in a thermal cycler (Eppendorf, Germany). The resulting cDNAs were stored at -20°C prior to RT-qPCR analyses.
Table 1. Primers Used for Reverse-Transcription and RT-qPCR Assay of the Target miRNAs

| Target | Primer Sequences (5' → 3') |
|--------|---------------------------|
| miR-214 | S: 5’-GTCGTATCGAGAGCAGGGTCCGAGGTATTCGCACTCGATACGACACTGCC-3’<br>F: 5’-ACACGAGGACAGACACAGGAGT-3’ |
| miR-6510 | S: 5’-GTCGTATCGAGAGCAGGGTCCGAGGTATTCGCACTCGATACGACCTGCAG-3’<br>F: 5’-CACCGACTCTGTCTCCTGCAG-3’ |
| miR-5193 | S: 5’-GTCGTATCGAGAGCAGGGTCCGAGGTATTCGCACTCGATACGACACTGGG-3’<br>F: 5’-TCCTCCTCTACCTCATCCCAGTG-3’ |
| miR-34a | S: 5’-GTCGTATCGAGAGCAGGGTCCGAGGTATTCGCACTCGATACGACACAACCA-3’<br>F: 5’-TGGCAGTGTCTTAGCTGGTTG-3’ |
| miR-103 | S: 5’-GTCGTATCGAGAGCAGGGTCCGAGGTATTCGCACTCGATACGACCAAGGCA-3’<br>F: 5’-GCTTCTTTACAGTGCTGCC-3’ |
| Common reverse | S: 5’-AGAGCAGGGTCCGAGGT-3’<br>F: 5’-AGAGCAGGGTCCGAGGT-3’ |

3.5. Quantitative Real-time PCR

All RT-qPCR analyses were performed using a LightCycler 96 instrument (Roche, Germany) in triplicates. The reaction mixture contained 7.5 μL of 1x SYBR Green Premix-ExRaq II (Yekta Tajhiz Azma, Iran), 0.45 μL of sense primer (10 μM concentration), 0.45 μL of antisense primer (10 μM concentration), 1.5 μL of cDNA template, and 5.1 μL of nuclease-free water. The thermal cycling condition was as follows: 95°C for 3 minutes, 40 cycles of 95°C for 10 seconds, 54°C for 10 seconds, and 72°C for 15 seconds. Melting curve analysis was carried out following amplification with a ramp rate of 0.2°C/sec to 96°C with constant fluorescence detection.

3.6. Statistical Analyses

The relative expression was analyzed by the comparative Cq method using the relative expression software tool (REST) (25). RT-qPCR data were expressed as means ± SE. Receiver operating characteristic (ROC) curve analysis was used to estimate the diagnostic capability of miRNA levels. The ROC analysis was performed using SPSS software (version 16). P values of < 0.05 were defined as statistical significance.

4. Results

4.1. miRNA Prediction Results

Based on the predicted results of the Miranda, miRBase, PicTar, TargetScan, mirWalk, and DIANA algorithms, the miRNAs with the highest scores were defined as Notch1-targeting miRNAs (Table 2). Among these miRNAs, miR-34a, which was a consensus target in most of the databases, was selected as the targeting miRNA. The prediction results for HBx-targeting miRNAs using miRBase and MirVir (Table 3) showed that miR-5193, miR-214, and miR-6510 had the highest scores and lowest E-values. In addition, they had the best complementarities with the target gene, so they were selected for further evaluation.

4.2. Quantification of miRNA Plasma Levels

As summarized in Figure 1, the RT-qPCR analysis showed that the expression level of miR-214 was significantly lower in the HCC group than in healthy controls (0.461, P = 0.008) and patients with chronic HBV (0.452, P = 0.023). Similarly, the expression levels were 0.236 (P = 0.001) and 0.402 (P = 0.47) for miR-6510, 0.053 (P = 0.000) and 0.175 (P = 0.000) for miR-5193, and 0.228 (P = 0.003) and 0.416 (P = 0.143) for miR-34a, respectively (Figure 1).

The expression levels of the four miRNAs were also compared between healthy individuals and patients with chronic HBV. The plasma level of miR-5193 (0.304, P = 0.012) was significantly lower in patients with chronic HBV, whereas the levels of miR-214 (1.02, P = 0.96), miR-6510 (0.688, P = 0.208), and miR-34a (0.549, P = 0.179) exhibited no statistical differences between the two groups (Figure 1).

4.3. Determination of Expression Level Cutoff

ROC curve analyses were performed to determine the cutoff values of miR-214, miR-6510, miR-5193, and miR-34a, to differentiate HCC patients from healthy individuals and patients with chronic HBV infection. The cutoff levels on the ROC curves were selected using the Youden’s index [(sensitivity + specificity) -1]. Comparisons of the miRNA
Table 2. The Result of miRNA Prediction for Notch1

| Gene Name | miRNA      | miRWalk | PicTar | Miranda | Targetscan | miRBase | DIANA | SUM |
|-----------|------------|---------|--------|---------|------------|---------|-------|-----|
| NOTCH1    | has-miR-34a | 1       | 1      | 1       | 1          | 0       | 1     | 5   |
| NOTCH1    | has-miR-200b| 0       | 0      | 1       | 1          | 0       | 1     | 3   |
| NOTCH1    | has-miR-34c | 0       | 1      | 1       | 1          | 0       | 0     | 3   |
| NOTCH1    | has-miR-139 | 1       | 1      | 1       | 1          | 0       | 0     | 4   |
| NOTCH1    | has-miR-449a| 1       | 0      | 1       | 1          | 0       | 1     | 4   |
| NOTCH1    | has-miR-200c| 0       | 0      | 1       | 0          | 0       | 0     | 1   |

Table 3. The Result of miRNA Prediction for HBx

| Gene Name | Predicted miRNA by miRBase | E Value | Score | Predicted miRNA by miRVir | E Value | Score |
|-----------|----------------------------|---------|-------|---------------------------|---------|-------|
| HBx       | hsa-miR-5193               | 1.6     | 74    | miR-3180                  | 2.8     | 66    |
| HBx       | hsa-miR-214                | 1.9     | 73    | miR-714                   | 6.0     | 62    |
| HBx       | hsa-miR-5193               | 1.2     | 67    | miR-6510                  | 6.2     | 61    |
| HBx       | hsa-miR-214                | 1.9     | 73    | miR-6744                  | 7.2     | 61    |

Figure 1. Differential expression levels of miR-214, miR-650, miR-5193, and miR-64a. A, comparison between HCC patients and healthy individuals; B, comparison between HCC patients and chronic HBV patients; C, comparison between chronic HBV patients and healthy individuals. Error bars indicate the standard error of the mean. *P < 0.05, **P < 0.01, significantly different from the control group.

plasma levels between HCC patients and healthy individuals showed that at the cutoff level of 0.792, miR-214 had 76% sensitivity and 74% specificity with an area under the curve (AUC) of 0.747. For miR-6510, at the cutoff level of 0.839, these values were 72% sensitivity and 91% specificity, with an AUC of 0.839. The best sensitivity and specificity were observed with miR-5193, which, at the cutoff point of 0.266, had 96% sensitivity, 100% specificity, and an AUC of 0.993. At the cutoff point of 0.446, miR-34a exhibited 92% sensitivity and 60% specificity, with an AUC of 0.736 (Figure 2).
On the other hand, in the comparison between HCC patients and chronic HBV patients, at the cutoff point of 0.806, the sensitivity, specificity, and AUC for miR-214 were 85%, 43%, and 0.52, respectively. The cutoff point of 0.914 for miR-6510 had a sensitivity of 81%, specificity of 39%, and AUC of 0.531. For miR-5193, at the cutoff point of 0.612, these values were 79.8% sensitivity and 82% specificity, with an AUC of 0.817. For miR-34a, the cutoff level of 0.584 exhibited 40% sensitivity and 87% specificity, with an AUC of 0.619 (Figure 3).

5. Discussion

Several studies have shown that alterations in microRNAs expression are related to the development and progression of various types of human malignancies. The pro-
files of these miRNAs vary depending on the tumor type, making them novel biomarkers for the diagnosis of different types of cancer including HCC (26). Chronic infection with HBV is one of the main risk factors for the onset and development of HCC, and the viral HBx protein could contribute to a multistep transformation process by affecting specific signal transduction pathways. A few studies have indicated that HBx can dysregulate important signaling pathways, including Notch, and that Notch signaling dysregulation is strongly related to HCC progression (10, 12, 14).

Most studies concerning the detection of miRNAs in cancers have been conducted on tissue samples as an invasive method for cancer diagnosis (27). Several reports have shown the stability of miRNAs in plasma and serum, which might be due to their protection by high-density
lipoproteins, exosomes, microvesicles, and Argonaute 2 (28). Therefore, circulating miRNAs could be useful as novel biomarkers for cancer diagnosis or staging. The focus of the present study was, therefore, on the comparative expression of miR-214, miR-6510, miR-5193, and miR-34a using RT-qPCR in the sera of patients with HCC and patients with chronic hepatitis B. These miRNAs were chosen using several algorithms used for the prediction of mRNA-miRNA interactions.

The plasma levels of these four miRNAs, as determined by RT-qPCR, were significantly lower in the HCC group than in the healthy control group. The expression of miR-214, miR-6510, miR-5193, and miR-34a was downregulated by 2.17, -4.23, -18.86, and -4.38 folds, respectively. Comparisons with chronic hepatitis B patients revealed no significant difference in the expression levels of miR-34a and miR-6510. The expression level of miR-5193, on the other hand, was downregulated by -5.71 folds in the HCC group compared to chronic HBV patients. The comparison of the expression levels between the healthy control and chronic HBV groups revealed significant differences only for miR-5193.

Several studies have identified a reduction in the miR-214 level in HCC tissues and cell lines (29), but none of the previous studies evaluated the plasma levels of this molecule as a potential biomarker for HCC. MiR-214 is thought to induce its effects by targeting essential molecules in the cell cycle, including maternal embryonic leucine zipper kinase (MELK) mRNA, β-catenin, and zeste homolog 2 (EZH2) (30). MiR-214 might also suppress the development of HCC by targeting E2F3 (31). The bioinformatics predictions in the current study indicated that miR-214 might directly target the HBx mRNA of the virus. Therefore, HCC progression may be prevented by the expression of miR-214 in cancer tissues through decreases in the expression of HBx protein.

The bioinformatics predictions presented here also indicated that miR-34a could target the transcript of the Notch1 gene, as the plasma level of this miRNA was decreased in patients with HCC. The decreased expression of miR-34a has also been reported in the tumorigenesis and progression of many types of cancer, including HCC (32, 33). MiR-34a was reported as a biomarker for predicting the risk of bone metastasis in HCC patients (34). More recently, the downregulation of miR-34a has been associated with disease progression of a poor-prognosis type of pancreatic ductal adenocarcinoma (PDAC) that was resistant to chemotherapy (35). The same study also implied that miR-34a exerted its effect through the inhibition of the Notch1-related signaling pathways.

On the other hand, miR-6510 is a newly identified microRNA for which no biological role has yet been described in the literature. The present study is the first report of the biological function of this molecule. The plasma level of this molecule was significantly reduced in patients suffering from HCC when compared to healthy individuals and patients with chronic HBV infection (-4.23 and -2.48 folds, respectively). Nonetheless, similar to the observations for miR-214 and miR-34a, the plasma level of miR-6510 was not significantly different between healthy people and patients with chronic hepatitis B. These findings confirm that the observed downregulations are related to HCC and not to chronic infection with hepatitis B virus.

In the present study, the most marked aberrant expression was observed for miR-5193 (Figure 1). To our knowledge, there is only one other study in the literature regarding this molecule, reporting that miR-5193 targets HBV transcripts in all HBV genotypes and that this miRNA has a role in HBV replication (36). This information confirms our bioinformatics prediction regarding miR-5193. The RT-qPCR results in the present study showed that the normalized fold changes for miR-5192, when compared to healthy individuals and patients with chronic HBV, were -18.85 and -5.7, respectively. Moreover, when compared to the levels in healthy individuals, this molecule was downregulated in patients with chronic hepatitis B (-3.28 folds). This suggests that this molecule may have an association with HCC through a direct role in HBV persistence.

The biggest challenge in the current study was the small sample size. However, since the prevalence of HDV in Iran is low and it is found lower than 1% in chronic HBV patients and lower than 5% in cirrhotic HBV patients (37), we believe that the HCC group was not populated by individuals with HDV infection and thus, the small sample size in the current study did not influence the obtained results.

The ROC curve analyses were also performed to assess the possibility of using plasma levels of these four miRNAs as diagnostic biomarkers for detecting HCC. In the first calculation, the microRNA levels were compared between HCC patients and healthy individuals. The values for miR-34a and miR-6510 were reasonable, but miR-5193 showed the greatest AUC, sensitivity, and specificity as 96%, 100%, and 0.993, respectively, at a cutoff of 0.266 (Figure 2). Therefore, differences in the expression of miR-5193 could accurately distinguish healthy individuals from patients with HCC, with excellent sensitivity and specificity.

The second ROC analysis compared the plasma levels of the miRNAs between the HCC and chronic HBV groups. The best values were again obtained for miR-5193, which showed sensitivity, specificity, and AUC of 79.8%, 82%, and 0.817, respectively, at a cutoff of 0.612. The values obtained for the other miRNAs examined were not discriminatory between HCC and HBV patients.
Conclusion

In conclusion, the results of the current study showed that the four predicted miRNAs were downregulated in the plasma of patients with HCC and thus, they may have roles in HCC development and progression. Of the miRNAs examined, miR-5193 appears to be a particularly promising candidate to serve as a novel non-invasive biomarker for the detection of HBV-induced HCC.

Acknowledgments

The authors thank Elham Taheri for her assistance in this survey.

Footnotes

Authors’ Contribution: Niloofar Moradi and Mehdi Paryan carried out the experiments and assays and collected the data. Behzad Khansarinejad developed the theory, performed the statistical analysis, and verified the analytical methods. Hossein Sarmandian collected clinical data and verified the analytical methods. Mahdieh Mondanizadeh conceived and planned the experiments and supervised the findings of research. All authors discussed the results and contributed to the final manuscript preparation.

Conflict of Interests: The authors have no conflict of interest to declare in relation to this manuscript.

Ethical Considerations: The study was approved by the Ethics Committee of Arak University of Medical Sciences (ethics number: 1394.207).

Funding/Support: This study was supported by the Research Deputy of Arak University of Medical Sciences (grant agreement No., 3244/395).

References

1. Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: Special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014;7(4):148-55. doi: 10.1177/1756283X14524614. [PubMed: 25057295]. [PubMed Central: PMC4107707].

2. World Health Organization. Hepatitis B. 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.

3. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24(3):51-7. doi: 10.1016/j.soc.2014.09.005. [PubMed: 25444466].

4. Akamatsu S, Hayes CN, Tsuge M, Miki D, Akiyama R, Abe H, et al. Differences in serum microRNA profiles in hepatitis B and C virus infection. J Infect. 2015;70(3):273-87. doi: 10.1016/j.jinf.2014.10.017. [PubMed: 25452043].

5. Zhang Y, Wei C, Guo CC, Bi RX, Xie J, Guan DH, et al. Prognostic value of microRNAs in hepatocellular carcinoma: A meta-analysis. Oncotarget. 2017;8(6):107727-57. doi: 10.18632/oncotarget.20883. [PubMed: 29291025]. [PubMed Central: PMC5739810].

6. Wang Y, Gao Y, Shi W, Zhai D, Rao Q, Jia X, et al. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark. 2015;15(2):77-80. doi: 10.3233/CBM1440451. [PubMed: 25509099].

7. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-4271. et al. doi: 10.1053/j.gastro.2012.12.001. [PubMed: 22574752]. [PubMed Central: PMC3358949].

8. Leverero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. / Hepatol. 2016;64(1 Suppl):S84-S80. doi: 10.1016/j.hep.2016.02.021. [PubMed: 27084040].

9. Tang Q, Wang Q, Zhang Q, Lin SY, Zhu Y, Yang X, et al. Gene expression, regulation of DEN and HBX induced HCC mice models and comparisons of tumor, para-tumor and normal tissues. BMC Cancer. 2017;17(1):362. doi: 10.1186/s12885-017-3860-x. [PubMed: 29254483]. [PubMed Central: PMC5735860].

10. Sun Q, Wang R, Wang Y, Luo J, Wang P, Cheng B. Notch is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma. Oncol Rep. 2014;31(2):933-9. doi: 10.3892/or.2013.2971. [PubMed: 24336972].

11. Wang F, Zhou H, Yang X, Xiu X, Sun Q, Luo J, et al. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep. 2012;27(4):1670-6. doi: 10.3892/or.2012.1620. [PubMed: 22218807]. [PubMed Central: PMC3538345].

12. Wang F, Xiu X, Wang J, Sun Q, Luo J, Cheng B. Notch signaling contributes to the oncogenic effect of HBX on human hepatic cells. Biotechnol Lett. 2013;35(1):29-37. doi: 10.1007/s10529-012-0487-8. [PubMed: 22986536].

13. Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch cleavage. Hepatology. 2010;52(3):1142-54. doi: 10.1002/hep.23861. [PubMed: 20578140].

14. Sun Q, Wang R, Luo J, Wang P, Xiong S, Liu M, et al. Notch promotes hepatitis B virus X protein-induced hepatocarcinogenesis via Wnt/beta-catenin pathway. Int J Oncol. 2014;45(1):1638-48. doi: 10.3892/ijon.2014.2537. [PubMed: 25017705].

15. Gao J, Xiong Y, Wang Y, Wang Y, Zheng G, Xu H. Hepatitis B virus X protein activates Notch signaling by its effects on Notch1 and Notch4 in human hepatocellular carcinoma. Int J Oncol. 2016;48(1):29-37. doi: 10.3892/ijon.2015.3211. [PubMed: 2653064].

16. Koberle V, Kronenberg B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhaj J, et al. Serum microRNA-141 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442-9. doi: 10.1016/j.ejca.2013.06.002. [PubMed: 23810247].

17. Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for hepatocellular carcinoma. Biomark Cancer. 2017;9:5-9. doi: 10.1186/s12943-016-0523-5. [PubMed: 27189160]. [PubMed Central: PMC5495498].

18. Mao B, Wang G. MicroRNAs involved with hepatocellular carcinoma (review). Oncol Rep. 2015;34(6):2811-20. doi: 10.3892/opr.2015.4275. [PubMed: 26388882].

19. Giordano S, Colombano A. MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57(2):840-7. doi: 10.1002/hep.26095. [PubMed: 2308718].

20. Abedi N, Mohammadi-Yeganeh S, Koochaki A, Karami F, Paryan M. miR-141 as potential suppressor of beta-catenin in breast cancer. Tumour Biol. 2013;36(2):5895-901. doi: 10.1007/s12087-013-3783-y. [PubMed: 25646002].

21. Endzelins E, Melne V, Kalnina Z, Lietuvietis V, Riekstina U, Llorente M. miR-22 in prostate cancer: A systematic review. Mol Cancer. 2016;15(1):1. doi: 10.1186/s12943-016-0523-5. [PubMed: 27898160]. [PubMed Central: PMC4870749].

22. Moradi N, et al. Hepat Mon. 2019;19(2):e84455.
22. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9(9). e107986. doi: 10.1371/journal.pone.0107986. [PubMed: 25238238]. [PubMed Central: PMC4169601].

23. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781–8. doi: 10.1200/JCO.2011.38.2697. [PubMed: 22105822].

24. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9). e36. doi: 10.1093/nar/gni178. [PubMed: 11972351]. [PubMed Central: PMC113859].

25. Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30. doi: 10.1002/jcp.25056. [PubMed: 26031493].

26. Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30. doi: 10.1002/jcp.25056. [PubMed: 26031493].

27. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Gastroenterol. 2018;53(4):355–60. doi: 10.1007/s00535-017-1565-8. [PubMed: 28278583].

28. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Gastroenterol. 2018;53(4):355–60. doi: 10.1007/s00535-017-1565-8. [PubMed: 28278583].

29. Pan JH, Zhou H, Zhao XX, Ding H, Li W, Qin L, et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (review). Int J Mol Med. 2018;41(4):1809–16. doi: 10.3892/ijmm.2018.3383. [PubMed: 29328416]. [PubMed Central: PMC5610235].

30. Pan JH, Zhou H, Zhao XX, Ding H, Li W, Qin L, et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (review). Int J Mol Med. 2018;41(4):1809–16. doi: 10.3892/ijmm.2018.3383. [PubMed: 29328416]. [PubMed Central: PMC5610235].

31. Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30. doi: 10.1002/jcp.25056. [PubMed: 26031493].

32. Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30. doi: 10.1002/jcp.25056. [PubMed: 26031493].